CSIMarket
 
Sonnet Biotherapeutics Holdings Inc   (SONN)
Other Ticker:  
 
 
Price: $2.0200 $0.35 20.958%
Day's High: $2.1199 Week Perf: -2.42 %
Day's Low: $ 1.67 30 Day Perf: 29.49 %
Volume (M): 142 52 Wk High: $ 26.40
Volume (M$): $ 286 52 Wk Avg: $5.00
Open: $1.68 52 Wk Low: $0.32



 Market Capitalization (Millions $) 8
 Shares Outstanding (Millions) 4
 Employees -
 Revenues (TTM) (Millions $) 0
 Net Income (TTM) (Millions $) -14
 Cash Flow (TTM) (Millions $) 1
 Capital Exp. (TTM) (Millions $) 0

Sonnet Biotherapeutics Holdings Inc
Sonnet Biotherapeutics Holdings Inc is a biotechnology company that specializes in developing innovative targeted immunotherapies for cancer treatments. The company focuses on utilizing its proprietary platform technology, called Immunopeptidomics, to create personalized medicines for patients with various types of cancer. Sonnet's approach involves identifying and targeting specific peptides expressed on cancer cells, leading to more effective and personalized treatments that can potentially enhance patient outcomes. The company's goal is to revolutionize cancer therapy by providing patients with highly personalized and targeted treatments that harness the power of the immune system to fight cancer.


   Company Address: 100 Overlook Center Princeton 8540 NJ
   Company Phone Number: 375-2227   Stock Exchange / Ticker: NASDAQ SONN
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Sonnet Biotherapeutics Holdings Inc

Sonnet Biotherapeutics Holdings Inc Successfully Narrows Losses in Recent Fiscal Period 2.

Sonnet Biotherapeutics Holdings Inc: A Bullish Turnaround Story
In the recently concluded fiscal period from October to December 2023, Sonnet Biotherapeutics Holdings Inc (NASDAQ: SONN) showcased significant improvements in its financial performance, demonstrating a promising shift from previous years. During this period, the company reported a loss of only $-0.31 per share, a remarkable improvement from the $-17.60 loss per share a year before, and a complete turnaround from the $0.00 per share reported in the preceding financial reporting period.
The reduction in losses can be attributed to several factors, one of which is the notable decline in revenue. Although revenue decreased by -50.004% to $0.02 million compared to the same period last year, this decline is significantly less severe when compared sequentially, with revenue tumbling by -74.727% from $0.07 million. This indicates that Sonnet Biotherapeutics Holdings Inc has been able to mitigate the negative impact of declining revenues and effectively manage its costs and expenditures.

Sonnet Biotherapeutics Holdings Inc

Breaking down Q4 2023: Sonnet Biotherapeutics Makes Strides in Revenue, but Struggles to Convert it into Profits



Sonnet Biotherapeutics Holdings Inc, a major player in the pharmaceutical preparations industry, reported notable revenue growth in the most recent fiscal period. However, the company failed to convert this revenue into profits, reflecting the challenges facing the industry. This article aims to interpret the financial results and provide an overview of the situation.
1. Revenue Surge but Profit Stagnation:
In the most recent fiscal period, Sonnet Biotherapeutics Holdings Inc experienced a significant revenue surge of 17.445% to $0.07 million. However, despite this growth, the company failed to increase its profits, which remained flat at $0.00 per share, year on year. This indicates a potential struggle to convert revenue into sustainable profits.

Sonnet Biotherapeutics Holdings Inc

Major Pharmaceutical Preparations Sector Plummets by Jaw-Dropping -40.633%, Sonnet Biotherapeutics Faces Uphill Battle



The stock market is a dynamic and often unpredictable arena, where companies' financial performance can vary greatly from one period to another. In recent news, the Major Pharmaceutical Preparations sector experienced a setback as the company declared disappointing financial results for its most recent fiscal period. Additionally, Sonnet Biotherapeutics Holdings Inc, a key player in the sector, also faced challenges. This article will delve into the specifics of these developments and shed light on interesting facts surrounding these events.
Major Pharmaceutical Preparations Sector's Decline:
The Major Pharmaceutical Preparations company witnessed a sharp decline in its revenue, plummeting by an astonishing -40.633% to $0.04 million. Such a significant decline raises concerns within the industry and may indicate possible underlying issues that need addressing. With a financial period ending on June 30, 2023, it is crucial for the company to strategize and reassess its current position in order to regain stability and profitability.






 

Sonnet Biotherapeutics Holdings Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com